Canada Post Corp Registered Pension Plan Makes New $478,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Canada Post Corp Registered Pension Plan bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,150 shares of the medical device company's stock, valued at approximately $478,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc purchased a new position in shares of DexCom during the fourth quarter worth about $25,000. Private Trust Co. NA lifted its holdings in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the period. TD Private Client Wealth LLC grew its holdings in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC raised its position in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock worth $8,044,178 over the last quarter. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DXCM. Cfra Research raised DexCom to a "hold" rating in a research note on Friday, March 21st. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Canaccord Genuity Group lifted their price objective on DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $99.00.

DexCom Stock Down 4.1 %

Shares of DexCom stock traded down $2.84 during trading on Monday, reaching $65.74. The company had a trading volume of 398,092 shares, compared to its average volume of 4,207,663. The company has a market cap of $25.78 billion, a price-to-earnings ratio of 45.97, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $139.24. The firm's fifty day moving average is $74.98 and its 200-day moving average is $76.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.